The meeting was organised to promote interaction and discussion bearing in mind the virtual setting limitations. To this end, the event was designed to facilitate crosstalk between work packages (WPs). During the different crosstalk sessions, WPs leads shared information on key activities and plans for the upcoming months. Their presentations were followed by discussions on the interdependencies, synergies and challenges to be faced in the project.
For instance, WP3 (Clinical Validation Studies) and WP4 (Biomarker Identification Validation) discussed the RESCEU clinical studies and the impact the shift in seasonality of RSV cases caused by COVID-19 may have on patient recruitment and the biomarker study. They agree on a course of action to mitigate any potential risks to PROMISE in this regard.
Synergies were also discussed regarding WP1 work on RSV epidemiology and impact of COVID-19 which feeds into WP2 (Preparation for future RSV product assessment). In terms of challenges, a discussion on how to handle sensitive topics in a public-private partnership (PPP) was held, where both public and private perspectives were outlined.
Overall, opportunities to share data and results across the various WP were discussed highlighting a synergistic and collaborative nature of this PPP. Following this stimulating and enlightening discussions, the PROMISE participants look forward to the next GAM in September 2022.